Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 110, Issue 11, Pages 1580-1588
Publisher
Wiley
Online
2012-09-18
DOI
10.1111/j.1464-410x.2012.11445.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial.
- (2017) R. B. Montgomery et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.
- (2017) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract A221: Results of preclinical and clinical phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in castrate-resistant prostate cancer
- (2012) B. Montgomery et al. MOLECULAR CANCER THERAPEUTICS
- SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
- (2011) Ming Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
- (2011) K.-H. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
- (2010) Dana Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Epigenetic regulation of androgen receptor signaling in prostate cancer
- (2010) Lina Gao et al. Epigenetics
- 17α-Alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism
- (2010) Clarence Ahlem et al. INVESTIGATIONAL NEW DRUGS
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- The epigenome as a therapeutic target in prostate cancer
- (2010) Antoinette S. Perry et al. Nature Reviews Urology
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity
- (2010) Hiromitsu Kawata et al. PROSTATE
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models
- (2009) Claudio Festuccia et al. ENDOCRINE-RELATED CANCER
- Testosterone and Prostate Cancer: Revisiting Old Paradigms
- (2009) Hendrik Isbarn et al. EUROPEAN UROLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
- (2009) Jennifer A. Locke et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP
- (2009) A. R. Karpf et al. MOLECULAR CANCER RESEARCH
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started